Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glembatumumab vedotin in advanced breast cancer
NCT00704158Phase 2Completed
- Sponsor
- CuraGen Corporation
- Start
- Jun 2008
- Primary completion
- Nov 2010
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of glembatumumab vedotin in breast cancer, sponsored by CuraGen Corporation. Started Jun 2008; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00704158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704158.